Winnergy Medical Public Company (WINMED) Fair Value & Analysis
Healthcare · TH · Market cap 316M THB
Fair value as of: Jun 24, 2026
Analysis
Winnergy Medical Public Company (WINMED) currently trades at 0.7800 THB, while our model-based Fair Value estimate is 0.8300 THB — implying the stock looks roughly 6.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Winnergy Medical Public Company Limited engages in the distribution of medical and diagnostic equipment in Thailand. The company imports and distributes technology and diagnostic kits for cervical cancer screening, including cytology examinations using automatic slide preparation machines and testing for human papilloma virus, and colposcopes. It also offers equipment for testing blood quality and blood collection bags for blood donation; blood quality testing products; blood freezers; blood banking, including pathogen inactivation; blood bag tube sealer; blood donor chairs; instrument for counting the number of leukocytes residual in blood; and device used to cut and connect both dry and wet blood bags. In addition, the company sells mosquito trappers for outdoor and indoor use; and offers HPV and STI self-collect test kits under AVA name. The company was formerly known as Winnergy Medical Co., Ltd. and changed its name to Winnergy Medical Public Company Limited in September 2020. …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Winnergy Medical Public Company (WINMED) undervalued?
What is the fair value of WINMED?
What is the quality score of WINMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.